Chi-Chao Chao
Overview
Explore the profile of Chi-Chao Chao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kao T, Hung Y, Yu A, Cheng M, Su M, Chao C, et al.
JACC Adv
. 2025 Feb;
4(2):101511.
PMID: 40021267
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) has recently gained recognition as a rare and fatal disease. Tafamidis, a first-in-class transthyretin stabilizer, has emerged as a promising agent for attenuating disease progression....
2.
Lin C, Hsueh H, Chiang M, Hsieh S, Chao C
Pain
. 2025 Feb;
PMID: 39968916
Degeneration of peripheral nerves causes neuropathic pain. Previous studies have documented structural and functional brain alterations in peripheral neuropathy, which may be attributed to maladaptive plasticity following chronic neuropathic pain....
3.
Conceicao I, Berk J, Weiler M, Kowacs P, Dasgupta N, Khella S, et al.
J Neurol
. 2025 Feb;
272(2):182.
PMID: 39899052
No abstract available.
4.
Chao C, Yang W, Yeh T, Kan Y, Wang Y, Lee K, et al.
Brain
. 2025 Jan;
PMID: 39874259
Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a neurodegenerative disease caused by mutations in the gene encoding transthyretin (TTR). Despite amyloid deposition being pathognomonic for diagnosis, this pathology in nervous...
5.
Yu A, Chen Y, Tsai C, Chao C, Su M, Shun C, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39800807
Objective: Tafamidis has shown potential in slowing disease progression in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate serial changes on [Tc]Tc-pyrophosphate (PYP) scintigraphy during tafamidis treatment...
6.
Yang Y, Tseng P, Chen C, Cheng Y, Wei J, Lin C, et al.
Am J Gastroenterol
. 2025 Jan;
PMID: 39760375
Introduction: The aim of this study was to quantitatively examine gastric mucosal nerve density (GMND) in patients with functional dyspepsia (FD) and analyzed its clinical correlation. Methods: We prospectively enrolled...
7.
Hsueh H, Chao C, Lin Y, Tseng P, Su M, Hsieh S
J Intern Med
. 2024 Oct;
296(6):495-509.
PMID: 39436674
Background: Hereditary transthyretin amyloidosis (ATTRv) is a hereditary disease that affects multiple bodily systems. Although sonography generally reveals enlargement of nerves in the limbs, the brachial plexus, and vagus nerve,...
8.
Hung Y, Yu A, Chen Y, Tsai C, Su M, Shun C, et al.
J Formos Med Assoc
. 2024 Oct;
PMID: 39389803
Background: RNA interference therapeutics reduce transthyretin production; however, their effect on hereditary transthyretin amyloid cardiomyopathy (ATTR-CA) remains unclear. We aimed to investigate alterations in technetium-99 m (Tc)-pyrophosphate (PYP) single-photon emission...
9.
Conceicao I, Berk J, Weiler M, Kowacs P, Dasgupta N, Khella S, et al.
J Neurol
. 2024 Aug;
271(10):6655-6666.
PMID: 39138650
Background: The phase 3 NEURO-TTRansform trial showed eplontersen treatment for 65 weeks reduced transthyretin (TTR), halted progression of neuropathy impairment, and improved quality of life (QoL) in adult patients with...
10.
Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis
Chao C, Tzeng S, Chiang M, Hsueh H, Hsieh W, Chao Y, et al.
Ann Clin Transl Neurol
. 2024 Aug;
11(9):2426-2438.
PMID: 39096004
Objectives: Hereditary transthyretin (TTR) amyloidosis (ATTRv) is frequently complicated by polyneuropathy (ATTRv-PN) and cardiomyopathy (ATTRv-CM). The long-term efficacy of diflunisal on both polyneuropathy and cardiomyopathy in ATTRv patients, especially those...